EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)

Peter A Fasching, Alexander Hein, Hans-Christian Kolberg, Lothar Häberle, Sabrina Uhrig, Matthias Rübner, Erik Belleville, Carolin C Hack, Tanja N Fehm, Wolfang Janni, Arndt Hartmann, Ramona Erber und 4 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.01.001 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Peter A Fasching und 15 weiteren Autor:innen. Beteiligte Einrichtung: Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlan…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsBreast NeoplasmsHumansFemaleTreatment OutcomeProspective StudiesPlatinumQuality of LifeCyclophosphamidePaclitaxelAnthracyclinesNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsEpirubicinAlbuminsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Neoadjuvant chemotherapyPD-L1PembrolizumabTriple-negative

Substanzen

PlatinumCyclophosphamidePaclitaxelAnthracyclinesEpirubicin130-nm albumin-bound paclitaxelAlbuminspembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany. Electronic address: peter.fasching@fau.de.
  • Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
  • Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
  • Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany; Biostatistics Unit, Department of Gynecology a…
  • ClinSol GmbH & Co KG, Würzburg, Germany.
  • Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Germany.

Zitieren

APA

Fasching, P. A., Hein, A., Kolberg, H. C., Häberle, L., Uhrig, S., Rübner, M., Belleville, E., Hack, C. C., Fehm, T. N., Janni, W., Hartmann, A., Erber, R., Theuser, A. K., Brucker, S. Y., Hartkopf, A. D., & Untch, M. (2023). Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.01.001

Vancouver

Fasching PA, Hein A, Kolberg HC, Häberle L, Uhrig S, Rübner M, et al. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041). European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.01.001

BibTeX
@article{Fasching2023,
  author = {Fasching, Peter A and Hein, Alexander and Kolberg, Hans-Christian and Häberle, Lothar and Uhrig, Sabrina and Rübner, Matthias and Belleville, Erik and Hack, Carolin C and Fehm, Tanja N and Janni, Wolfang and Hartmann, Arndt and Erber, Ramona and Theuser, Anna-Katharin and Brucker, Sara Y and Hartkopf, Andreas D and Untch, Michael},
  title = {Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.01.001}
}
Kostenlos starten →